Chemistry:Ro07-3953

From HandWiki

Ro07-3953 (Diflunordazepam) is a benzodiazepine derivative which is the 2',6'-difluoro derivative of nordazepam. It was invented in the 1970s but was never marketed,[1][2] however it has recently appeared on the market as a designer drug, first reported in Sweden in December 2024.[3][4]

See also

References

  1. ↑ "Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks". Journal of Medicinal Chemistry 38 (4): 715–724. February 1995. doi:10.1021/jm00004a017. PMID 7861419. 
  2. ↑ "Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors". Journal of Medicinal Chemistry 39 (26): 5246–5256. December 1996. doi:10.1021/jm960536o. PMID 8978853. 
  3. ↑ "EU Early Warning System – Formal Notification: EU‑EWS‑RCS‑FN‑2024‑0044 (Ro 07‑3953)". EU Early Warning System (EWS) / EUDA. 16 December 2024. https://workpage.ews-nfp.bg/wp-content/uploads/2024/12/EU-EWS-RCS-FN-2024-0044_Ro-07-3953.pdf. 
  4. ↑ "European Drug Report 2025 – Full Book". European Union Drugs Agency (euda.europa.eu). 6 June 2025. https://www.euda.europa.eu/system/files/documents/2025-06/edr-2025-full-book-6.06.2025-en.pdf. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Ro07-3953&oldid=4028996"